Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|October 1, 2007
Patricia Van Arnum
This is the bio for Patricia Van Arnum, senior editor of Pharmaceutical Technology magazine.
Advertisement
Patricia Van Arnum
Executive Editor
732.346.3072,
Patricia Van Arnum, executive editor, covers active pharmaceutical ingredients (APIs), intermediates, fine chemicals, advances in process R&D, formulation development, and finished drug-product manufacturing for Pharmaceutical Technology. She also is editor of Sourcing and Management, a monthly newsletter of Pharmaceutical Technology covering sourcing, the pharmaceutical supply-chain, API synthesis and manufacturing, and formulation development and finished drug-product manufacturing. Patricia has 20 years of experience as a business and science journalist and editor, which includes 17 years of experience covering the pharmaceutical and fine-chemicals industries. Patricia was formerly executive editor of Chemical Market Reporter (now ICIS Chemical Business) and was with CMR and ICIS from 1995–2005. She joined Pharmaceutical Technology as a senior editor in January 2006. She holds undergraduate degrees in chemistry, economics, and political science. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, the American Medical Writers Association, and the American Association for the Advancement of Science.
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement